Exclusive-China's aland Health seeking buyers at over $1.5 billion valuation, sources say

The controlling stake in Aland Health Holding, a global nutritional supplement manufacturer, is reportedly being offered for sale by its owners, including founder Chang Liang and investment firms like Goldman Sachs Growth Equity, targeting a valuation exceeding $1.5 billion. The company, on track for $150 million in annual EBITDA, is drawing preliminary interest from strategic buyers and private equity firms. A key attraction is Aland's significant U.S. manufacturing footprint through its IVC subsidiary, positioning it favorably amidst a rapidly growing global nutritional supplements market and ongoing supply chain reshoring trends, particularly in the U.S.

Analysis

The controlling stake in private Chinese nutritional supplement manufacturer Aland Health Holding is being marketed for sale, with owners targeting a valuation exceeding $1.5 billion. This valuation implies a multiple of over 10x the company's projected annual EBITDA of approximately $150 million, a key metric for potential private equity and strategic buyers. The primary strategic appeal of the asset is its significant U.S. manufacturing footprint through its subsidiary, International Vitamin Corporation (IVC), which positions it advantageously amid the ongoing trend of supply chain reshoring. This U.S. presence, coupled with its role as a private-label supplier to major retailers like Walmart and Costco, makes it an attractive target for entities looking to capitalize on strong domestic and global demand. The global nutritional supplements market is forecast to grow at a 6.4% CAGR through 2030, providing a supportive macro backdrop for the transaction. The deal is in its preliminary stages, with the moderately positive sentiment signal reflecting the value-unlocking potential of the M&A event for its current owners, including founder Chang Liang and investment firms like Goldman Sachs Growth Equity.

Key Decisions for Investors

• Investors in the consumer health and supplement sector should note the implied >10x EBITDA valuation for Aland, as the final sale price will set a significant valuation benchmark for companies with strong domestic manufacturing capabilities.
• Private equity firms and strategic buyers should closely examine the value of Aland's U.S.-based subsidiary (IVC) as a hedge against global supply chain volatility and a direct play on the U.S. reshoring trend.
• Given Aland’s role as a major private-label supplier, investors in its retail partners, such as Walmart and Costco, should monitor the M&A process for any potential impact on supply chain stability or pricing dynamics post-acquisition.